Prognostic biomarkers and clinical outcomes in neuroendocrine prostate cancer (NEPC).
Richard Gagnon(BC Cancer Agency), Steven Yip(University of Calgary), Tarek A. Bismar(University of Calgary), Kamiko R. Bressler(University of Calgary), Rehan M. Faridi(University of Calgary), Ealia Khosh Kish(University of Calgary), Richard M. Lee‐Ying(Alberta Health Services), Pinaki Bose(University of Calgary), Brian Yu Chieh Cheng(University of Calgary), Adrian Fairey(University of Alberta), Michael Kolinsky(University of Alberta), Kosuke Takemura(Japanese Foundation For Cancer Research), John D. Lewis(University of Victoria), Divya Samuel(University of Calgary), Sarah Cook(University of Calgary), Joseph D. Ruether, Catalina Vásquez, Nimira Alimohamed(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Minal Borkar(University of Calgary)
Cited by 3
Related Papers
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
A non-randomized comparison of mindfulness-based stress reduction and healing arts programs for facilitating post-traumatic growth and spirituality in cancer outpatients
|Supportive Care in Cancer|2007|269
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
<i>PTEN</i> genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
|The Journal of Pathology|2009|210
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
|Proceedings of the National Academy of Sciences|2008|182